Important COVID-19 Information for Cancer Patients: READ NOW
Now Offering Phone and Video Appointments for Cancer Care
Treatment with Bone Marrow Transplantation
Conditions We Treat with Bone Marrow Transplantation
The Fox Chase-Temple University Hospital Bone Marrow Transplantation Program treats patients with hematologic malignancies—from diagnosis through transplant, should one be needed, to ongoing follow-up care. Diseases successfully treated by our team include:
- Acute lymphoblastic leukemia
- Acute myelogenous leukemia
- Chronic lymphatic leukemia Rai Stage II-III
- Chronic myelogenous leukemia not responding to kinase therapy
- Multiple myeloma
- Myelodysplastic syndromes
- Primary amyloidosis
- Relapsed germ cell/testicular tumors
- Relapsed or high-risk non-Hodgkin's lymphoma
- Relapsed or refractory Hodgkin's disease
- Severe aplastic anemia or paroxysmal nocturnal hemoglobinuria
- Sickle cell anemia
- Other life-threatening blood disorders
Clinical Trials
Coming to Fox Chase means access to new cancer treatment options through our clinical trials
In addition to the latest treatments, Fox Chase is actively developing and evaluating a number of new therapies, often before they are available anywhere else. We encourage eligible patients to participate in clinical trials that are available and appropriate for their stage and type of cancer. Review our list of open clinical trials. Each listing includes qualifications and additional information about that specific trial.
Ask your Fox Chase doctor if a clinical trial is right for you. For more information about clinical trials, or to discuss your eligibility, please call the Office of Clinical Research at 215-214-1515 during normal business hours.
The Fox Chase-Temple Bone Marrow Transplant Program is fully accredited by the Foundation for the Accreditation of Cellular Therapy (FACT) and a participating provider in the National Marrow Donor Program (NMDP). In 2020 the BMT was reaccredited for adult allogeneic and autologous hematopoietic progenitor cell transplantation, peripheral blood cellular therapy product collection, and cellular therapy product processing with minimal manipulation. Also included was a new accreditation for immune effector cells.
Temple University Hospital earned “Blue Distinction Transplant – Bone Marrow/Stem Cell” from Blue Cross Blue Shield, in recognition of the Fox Chase-Temple University Hospital Bone Marrow Transplant (BMT) Program’s expertise in performing adult bone marrow transplants.
Blue Distinction Centers (BDC) met overall quality measures, developed with input from the medical community. A Local Blue Plan may require additional criteria for providers located in its own service area; for details, contact your Local Blue Plan. Blue Distinction Centers+ (BDC+) also met cost measures that address consumers’ need for affordable healthcare. Each provider’s cost of care is evaluated using data from its Local Blue Plan. Providers in CA, ID, NY, PA, and WA may lie in two Local Blue Plans’ areas, resulting in two evaluations for cost of care; and their own Local Blue Plans decide whether one or both cost of care evaluation(s) must meet BDC+ national criteria. National criteria for BDC and BDC+ are displayed on www.bcbs.com. Individual outcomes may vary. For details on a provider’s in-network status or your own policy’s coverage, contact your Local Blue Plan and ask your provider before making an appointment. Neither Blue Cross and Blue Shield Association nor any Blue Plans are responsible for non-covered charges or other losses or damages resulting from Blue Distinction or other provider finder information or care received from Blue Distinction or other providers.